Specifically, miR-34a has shown promise in targeting the C-MET gene, known to contribute to EGFR-TKI resistance, and successfully inhibiting the EGFR/PI3K/AKT pathway, thereby reversing Gefitinib resistance in NSCLC cells such as HCC827 (ATCC catalog #CRL-2868, harboring an exon 19 deletion in EGFR) and PC-9 (MilliporeSigma catalog #90071810-1VL, harboring an EGFR exon 19 deletion and often used as a gefitinib-sensitive model) [20,36]. The gene discussed is PIK3CB; the disease is non-small cell lung carcinoma.